Clinical Trial Update: An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis [Phase 4]

View source ↗

Summary

An open-label Phase 4 study evaluating the failure rate of the Enbrel SureClick auto-injector in adults with rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ENBREL (etanercept)

Snippet

Sponsor: Amgen | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED